PREVENTABLE: Cancer prevention vs cancer treatment: The rare tumour risk syndromes battle

可预防：癌症预防与癌症治疗：罕见肿瘤风险综合征之战

• 批准号: 10063800
• 金额: $ 39.19万
• 依托单位: LANCASTER UNIVERSITY
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10063800
• 关键词: PREVENTABLE; Cancer; prevention; vs; cancer

Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as high as 100%, and patients have a 50% chance of transmitting the disease to their offspring. When undiagnosed or not surveilled, many asymptomatic RTRS patients develop particularly aggressive cancers, leading to premature death, severely impacting theirs and their families’ health and wellbeing. Cancers in RTRS can be prevented and survival rates maximized if asymptomatic RTRS patients are intensively surveilled for RTRS-prone organs, cancer-prone organs are surgically removed prior to disease development, or very small cancerous or pre-cancerous lesions are removed or treated. RTRS are therefore a unique and tangible context for cancer prevention, early diagnosis and treatment with curative intent. However, risk-reduction strategies are not always prioritized in genetically diagnosed and asymptomatic RTRS patients, and most healthcare systems keep on opting for treatment of clinically expressed cancer. This occurs despite the knowledge that hospitalization has the highest weight on advanced cancer healthcare spending. It is therefore urgent to demonstrate the cost-benefit of the application of preventive measures in RTRS syndromes. The ambition of the PREVENTABLE project is to merge specialized clinical knowledge on RTRS pathways of care, reallife clinical data from RTRS patients and experiences from professionals and patients, with health economic models and social sciences approaches to estimate the cost-benefit of risk-reduction interventions in RTRS and delineate guidelines for its communication among and within clinical teams and RTRS patients. PREVENTABLE project results will be delivered to a diversity of stakeholders, including policy-makers, in order to promote the implementation of cost-effective RTRS patient-centered care in Europe.

罕见肿瘤风险综合征(RTR)是一种罕见的疾病，每10.000人中有5人患病，由可遗传的遗传变异引起。在RTRS中，一生中患各种癌症的风险可能高达100%，患者有50%的机会将疾病传播给他们的后代。如果没有诊断或监测，许多无症状的RTRS患者会患上特别侵袭性的癌症，导致过早死亡，严重影响他们及其家人的健康和福祉。如果对无症状的RTRS患者密切监测易患RTRS的器官，在疾病发展之前手术切除易患癌症的器官，或者切除或治疗非常小的癌症或癌前病变，则可以预防RTRS中的癌症，并最大限度地提高存活率。因此，RTR对于癌症预防、早期诊断和有治疗意图的治疗来说是一个独特和有形的背景。然而，在基因诊断和无症状的RTRS患者中，降低风险的策略并不总是优先考虑的，大多数医疗系统继续选择治疗临床表现的癌症。尽管知道住院在先进的癌症医疗支出中占有最高的权重，但这种情况还是发生了。因此，迫切需要证明在RTRS综合征中应用预防措施的成本效益。可预防项目的目标是将有关RTRS护理途径的专门临床知识、RTRS患者的真实临床数据和专业人员和患者的经验与卫生经济模型和社会科学方法结合起来，以评估RTRS中降低风险干预的成本效益，并为临床团队和RTRS患者之间的沟通制定指导方针。将向包括政策制定者在内的不同利益攸关方提供可预防的项目成果，以促进在欧洲实施具有成本效益的RTRS以患者为中心的护理。